Figure 1
Antitumor effects of individual or combined anti-TIM-3 and anti-CD137 mAbs in murine ID8 ovarian cancer model. Mice (5 or 10 mice/group) transplanted i.p. with 1 × 106 ID8 cells 3 (A, C) or 10 (B, D) day before were treated thrice with 250 μg of control, anti-TIM-3, anti-CD137 and anti-TIM-3/CD137 mAb at 4 days interval and overall survival of mice was recorded (A, B) and mean survival time of mice with tumor growth was calculated (C, D). The experiment was repeated once with similar result. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control mAb treated mice.